Capital World Investors Amgen Inc Transaction History

Capital World Investors

$592 Billion
Q1 2025

A detailed history of Capital World Investors transactions in Amgen Inc stock. As of the latest transaction made, Capital World Investors holds 16,701,609 shares of AMGN stock, worth $4.98 Billion. This represents 0.88% of its overall portfolio holdings.

Number of Shares

16,701,609

Previous 6,495,710 157.12%

Holding current value

$4.98 Billion

Previous $1.69 Billion 207.34%

% of portfolio

0.88%

Previous 0.27%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$258.59 - $327.36 $2.64 Billion - $3.34 Billion	10,205,899 Added 157.12%	16,701,609 $5.2 Billion
Q4 2024 Feb 13, 2025	BUY	$258.78 - $328.31 $1.56 Billion - $1.98 Billion	6,029,058 Added 1291.98%	6,495,710 $1.69 Billion
Q3 2024 Nov 13, 2024	BUY	$309.38 - $337.38 $144 Million - $157 Million	466,652 New	466,652 $150 Million
Q2 2020 Aug 14, 2020	SELL	$197.81 - $242.74 $16.5 Million - $20.2 Million	-83,298 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$182.24 - $241.7 $93.1 Million - $123 Million	-510,831 Reduced 85.98%	83,298 $16.9 Million
Q4 2019 Feb 18, 2020	BUY	$189.21 - $243.2 $33,300 - $42,803	176 Added 0.03%	594,129 $143 Million
Q3 2019 Nov 14, 2019	BUY	$174.11 - $208.62 $1,566 - $1,877	9 Added 0.0%	593,953 $115 Million
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $114 Million - $134 Million	-684,937 Reduced 53.56%	593,944 $109 Million
Q4 2018 Feb 14, 2019	SELL	$178.4 - $208.25 $592 Million - $691 Million	-3,318,062 Reduced 72.18%	1,278,881 $249 Million
Q3 2018 Nov 14, 2018	BUY	$185.29 - $208.89 $852 Million - $960 Million	4,596,943 New	4,596,943 $953 Million

Others Institutions Holding AMGN

# of Institutions

3,300

Shares Held

426M

Call Options Held

8.06M

Put Options Held

7.7M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $160B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.

Account

Capital World Investors Amgen Inc Transaction History